๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Shanghai
Clinical trial register · China

Clinical Trials in Shanghai, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Fudan University454 Ruijin Hospital276 Shanghai Zhongshan Hospital163 RenJi Hospital135 Children's Hospital of Fudan University84
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Shanghai

3827 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.
NCT05760378Triple-Negative Breast Cancer
DrugsFamitinib·Camrelizumab
Fudan University
Phase 3
223
Shanghai
2023-03-17
Recruiting
The Efficacy of Compression/Ice Gloves/Socks in Patients With UTD1-induced Neuropathy.
NCT07638774Locally Advanced or Metastatic Breast Cancer
Fudan University
Not applicable
324
Shanghai
2023-03-15
Recruiting
Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung Cancer
NCT05766800Locally Advanced, Non-small Cell Lung Cancer
DrugsLiposomal paclitaxel·Serplulimab·Nab-paclitaxel·Pemetrexed
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
100
Shanghai
2023-03-14
Active, closed
Different Targeted Antibody-drug Conjugates For HER2 Ultra-low or No Expression Advanced Breast Cancer๏ผˆGALAXY๏ผ‰
NCT05824325Breast Cancer
DrugsTROP2 ADC·Trastuzumab Rezetecan
Fudan University
Phase 1/2
56
Shanghai
2023-03-14
Recruiting
Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer
NCT05671822HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 2
258
Shanghai
2023-03-14
Recruiting
China Children Eye Study
NCT05770661Axial Length, Myopia, Child Development
Shanghai Eye Disease Prevention and Treatment Center
Observational
30,000
Shanghai
2023-03-10
Active, closed
Study of Low-Dose Radiotherapy Concurrent Chemotherapy With Serplulimab for Patients With ES-SCLC
NCT05765825Extensive-stage Small-cell Lung Cancer
DrugsSerplulimab·Etoposide·Cisplatin·Carboplatin
Sichuan University
Phase 2
61
Chongqing, Shantou, Wuhan, Shenyang, Jinan, Shanghai, Chengdu, Guiyang
2023-03-07
Recruiting
A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous Nephropathy
NCT05668403Primary Membranous Nephropathy
DrugB007
Shanghai Jiaolian Drug Research and Development Co., Ltd
Phase 1
52
Zhengzhou, Shijiazhuang, Hangzhou, Beijing, Shanghai
2023-03-02
Recruiting
A Phase I Study of HS-10386 in Participants With Advanced Solid Tumors
NCT05911464Advanced Solid Tumor
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1
248
Shanghai
2023-03-02
Recruiting
Longitudinal Data Registry of Plasma Cell Dyscrasia
NCT06760052Multiple Myeloma and Other Plasma Cell Neoplasms
Shanghai Zhongshan Hospital
Observational
2,000
Shanghai
2023-03-01
Recruiting
Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC
NCT05768503Metastatic Microsatellite-stable Colorectal Cancer
Sun Yat-sen University
Phase 3
176
Hefei, Foshan, Guangzhou, Nanning, Harbin, Zhengzhou, Nanchang, Shanghai
2023-03-01
Active, closed
Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer
NCT05759572Breast Cancer Metastatic
Fudan University
Phase 2
145
Shanghai
2023-03-01
Recruiting
Digitalized Surveillance Management for Liver Cancer Risk Population in Improving Eearly Diagnosis Efficancy in Chinese Population (dSEARCH)
NCT05870969Carcinoma, Hepatocellular, Hepatitis C, Chronic, Hepatitis B, Chronic, Cirrhosis, Liver
Ruijin Hospital
Observational
20,000
Shanghai
2023-03-01
Recruiting
Construction of Molecular Diagnostic Marker Model for Pancreatic Cystic Tumors Based on Pancreatic Cystic Fluid Samples
NCT05737953Pancreatic Neoplasms, DNA Methylation, Proteome
Zhaoshen Li
Observational
100
Shanghai
2023-03-01
Recruiting
An Exploratory Clinical Trial of VGN-R08b in Patients With Type II Gaucher Disease
NCT06272149Type II Gaucher Disease
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Phase EARLY_PHASE1
6
Shanghai
2023-03-01
Recruiting
Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients
NCT05771181Colorectal Cancer, Microsatellite Stable Colorectal Carcinoma
DrugsVitamin E·Fruquintinib·Tislelizumab
Fudan University
Phase 2
25
Shanghai
2023-03-01
Not yet open
CAPEOX vs Observation in Colorectal Cancer Patients With Positive MRD
NCT05699746Colorectal Cancer
DrugsOxaliplatin·Capecitabine
Zhejiang University
Phase 3
38
Shanghai, Hangzhou, Ningbo
2023-03
Not yet open
Imapct of bioMarkers on Pharmacodynamics and Bleeding Risk of Direct Oral AntiCoagulants and Ticagrelor Study II
NCT05764356Novel Oral Anticoagulants, NOACs, Rivaroxaban, Apixaban
Peking University First Hospital
Observational
2,000
Hefei, Beijing, Chongqing, Zhengzhou, Shanghai
2023-03
Recruiting
Plasma cfDNA Fragmentomics for Early pNET Detection and Differential Diagnosis of Solid Pancreatic Tumors
NCT05847855Pancreatic Neuroendocrine Tumor, Solid Pancreatic Neoplasms
Fudan University
Observational
1,000
Shanghai, Chengdu
2023-02-27
Active, closed
LX102 in Patients With Neovascular Age-Related Macular Degeneration (nAMD)
NCT06198413Neovascular Age-Related Macular Degeneration
Innostellar Biotherapeutics Co.,Ltd
Phase 1
12
Hefei, Hangzhou, Shanghai
2023-02-27
Active, closed
AR Training in Adults With Unilateral Amblyopia
NCT06704737Amblyopia Unilateral, Amblyopia Functional
Eye & ENT Hospital of Fudan University
Not applicable
48
Shanghai
2023-02-25
Recruiting
Neurofeedback-Based Digital Therapeutics for the Diagnosis and Treatment of ADHD in Children.
NCT06369714Attention Deficit Disorder With Hyperactivity, Executive Function Disorder
Lei Lei, MD
Not applicable
210
Shanghai
2023-02-24
Active, closed
A Study of ES014 in Patients With Locally Advanced or Metastatic Solid Tumours
NCT05717348Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor
DrugES014
Elpiscience (Suzhou) Biopharma, Ltd.
Phase 1
120
Shanghai
2023-02-24
Recruiting
A Study of KC1036 in Patients with Advanced Thymic Tumors
NCT05683886Thymic Tumors
DrugKC1036
Beijing Konruns Pharmaceutical Co., Ltd.
Phase 2
30
Shanghai, Chengdu
2023-02-22
Recruiting
A Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma
NCT05800977Relapsed/Refractory Large B-Cell Lymphoma
Shanghai AbelZeta Ltd.
Phase 1/2
112
Beijing, Chongqing, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Shanghai
2023-02-22
Active, closed
Functional ComprEhensive AssessmenT by IVUS Reconstruction in Patients With Suspected IschEmic Heart Disease (FEATURE)
NCT05694065Ischemic Heart Disease
Ruijin Hospital
Observational
112
Shanghai
2023-02-17
By invitation
Clinical Trial to Assess the Safety and Efficacy of EXG001-307 in Patients with Spinal Muscular Atrophy Type 1
NCT05614531Spinal Muscular Atrophy Type I
Guangzhou Jiayin Biotech Ltd
Phase 1/2
12
Shanghai, Hangzhou
2023-02-16
Recruiting
Segmentectomy for Ground Glass-dominant Invasive Lung Cancer (ECTOP-1012)
NCT05717803Segmentectomy, Lung Adenocarcinoma
Fudan University
Phase 3
307
Shanghai
2023-02-15
Recruiting
DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)
NCT06276283Non-small Cell Lung Cancer
DrugsSunvozertinib·Bevacizumab
Dizal Pharmaceuticals
Phase 2
60
Shanghai
2023-02-15
Recruiting
Genotype-guided Treatment in Newly Diagnosed PTCL
NCT05675813Peripheral T Cell Lymphoma
DrugsDuvelisib·CHOP·Selinexor·Chidamide
Ruijin Hospital
Phase 1/2
264
Shanghai
2023-02-13
Active, closed
A Study of SI-B001+SI-B003ยฑ Chemotherapy in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma
NCT05668858Squamous Cell Carcinoma of Head and Neck
DrugsSI-B001·SI-B003
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1/2
70
Shanghai
2023-02-10
Recruiting
SCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rectal Cancer
NCT05576480Rectal Cancer, Locally Advanced
DrugsCapeox·Penpulimab
Ruijin Hospital
Phase 2
55
Shanghai
2023-02-06
Recruiting
Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL)
NCT05681260T-cell Lymphoblastic Lymphoma
Children's Cancer Group, China
Phase 3
200
Shanghai, Chengdu
2023-02-06
Active, closed
A Study of APS03118 in Advanced Solid Tumors Harboring RET Mutations or Fusions
NCT05653869RET-altered Solid Tumors
Applied Pharmaceutical Science, Inc.
Phase 1
108
Shanghai
2023-02-06
Active, closed
Assessment of DOT Spectacles in Chinese Children
NCT05562622Juvenile Myopia, Myopia
SightGlass Vision, Inc.
Not applicable
195
Changsha, Chengdu, Guangzhou, Shanghai, Tianjin
2023-02-05
Recruiting
Autoimmune Hepatitis Cohort in China
NCT05785793Autoimmune Hepatitis
Shanghai Jiao Tong University School of Medicine
Observational
1,000
Shanghai
2023-02-01
Recruiting
Chemotherapy CLAGE-Ven Sequential With Reduced Intensity Conditioning for Refractory Acute Myelodi Leukemia
NCT05870995Refractory Leukemia
Shanghai Jiao Tong University School of Medicine
Phase 2
100
Shanghai
2023-02-01
Recruiting
A Randomized Controlled Trial Comparing Clinical Effectiveness of SMILE Versus SMILE Xtra in Myopia
NCT06992011Myopia
Shanghai Zhongshan Hospital
Not applicable
300
Shanghai
2023-02-01
Recruiting
PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer
NCT05759546Breast Cancer Metastatic
DrugsFulvestrant/AI·Fluzoparib·Dalpiciclib
Fudan University
Phase 2
200
Shanghai
2023-02-01
Recruiting
Gene Therapy for Subjects With RPGR Mutation-associated X-linked Retinitis Pigmentosa
NCT05874310X-Linked Retinitis Pigmentosa
Frontera Therapeutics
Phase EARLY_PHASE1
18
Beijing, Shanghai
2023-02-01
Active, closed
Novel Serum Biomarkers for Identifying Plaque Erosion in ACS and Predicting Prognosis
NCT06763835Plaque Rupture, Acute Coronary Syndromes
Xuebo Liu
Observational
301
Shanghai
2023-02-01
Recruiting
A Prospective Study on Clinical Effectiveness After SMILE Versus SMILE Xtra in Myopia
NCT06973278Myopia
Shanghai Zhongshan Hospital
Not applicable
200
Shanghai
2023-02-01
Recruiting
An Early Clinical Trial to Evaluate VGN-R09b for Treatment of Aromatic L-amino Acid Decarboxylase (AADC) Deficiency.
NCT05765981Aromatic L-amino Acid Decarboxylase (AADC) Deficiency
Shanghai Jiao Tong University School of Medicine
Phase EARLY_PHASE1
6
Shanghai
2023-01-30
Recruiting
Study of Cord Blood-derived CAR NK Cells Targeting CD19/CD70 in Refractory/Relapsed B-cell Non-Hodgkin Lymphoma
NCT05842707Refractory or Relapsed B-cell Non-Hodgkin Lymphoma
Aibin Liang๏ผŒMD๏ผŒPh.D.
Phase 1/2
48
Shanghai
2023-01-18
Recruiting
Study of SGN1 in Patients With Advanced Solid Tumor
NCT05038150Advanced Solid Tumor
DrugSalMet-Vec
Guangzhou Sinogen Pharmaceutical Co., Ltd
Phase 1/2
70
Guangzhou, Harbin, Shanghai, Chengdu
2023-01-16
Recruiting
Optimizing(O) RIfapentine-based(RI) Regimen and shortENing(EN) the Treatment of Drug-sensitive Tuberculosis(T)
NCT05401071Tuberculosis, Pulmonary
Huashan Hospital
Phase 2/3
2,442
Guiyang, Kaili, Liupanshui, Zunyi, Shanghai, Zhuji
2023-01-13
Recruiting
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
NCT05614739Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms
DrugsVepugratinib·Digoxin·Rosuvastatin·Enfortumab Vedotin
Eli Lilly and Company
Phase 1
677
Beijing, Guangdong, Hangzhou, Shanghai, Tianjin, Xi'an, Zhejiang
2023-01-12
Recruiting
A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors
NCT05615974Malignant Tumors
DrugsRituximab·Toripalimab
LaNova Medicines Limited
Phase 1/2
139
Guangzhou, Wuhan, Linyi, Beijing, Shanghai
2023-01-11
Active, closed
Leber Congenital Amaurosis Inherited Blindness of Gene Therapy Trial(LIGHT)
NCT06088992Leber Congenital Amaurosis
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Phase EARLY_PHASE1
9
Shanghai
2023-01-10
Recruiting
A Prospective Phase II Study for Adjuvant Hypofractionated Intensity-modulated Proton Radiotherapy for Post Operative Breast Cancer With Implantation Reconstruction
NCT05692674Breast Cancer
Shanghai Proton and Heavy Ion Center
Phase 2
67
Shanghai
2023-01-10
Recruiting
Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer
NCT06173986Esophageal Squamous Cell Carcinoma, Unresectable Locally Advanced Esophageal Cancer
DrugsPD-1inhibitor·Nab-paclitaxel·Cisplatin
Shanghai Chest Hospital
Phase 1/2
50
Shanghai
2023-01-10
Active, closed
A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease
NCT05662241IgG4 Related Disease
DrugObexelimab
Zenas BioPharma (USA), LLC
Phase 3
194
Beijing, Shijiazhuang, Wuhai, Yantai, Shanghai, Taiyuan, Chengdu
2023-01-09
Recruiting
A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection
NCT05489289Hepatocellular Carcinoma
DrugCadonilimab
Akeso
Phase 3
570
Shanghai
2023-01-05
Recruiting
Phase I Clinical Study of BL-M07D1 in Locally Advanced or Metastatic Digestive Tract Tumors and Other Solid Tumors
NCT05631964Locally Advanced or Metastatic Digestive Tract Tumors, Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
26
Shanghai
2023-01-05
Recruiting
Optimized Acupuncture Treatment for Female Stress Urinary Incontinence
NCT05635669Stress Urinary Incontinence
Yin Ping
Not applicable
360
Shanghai
2023-01-04
Active, closed
TCM Daoyin Therapy in Individuals At-risk for COPD
NCT05940480Chronic Obstructive Pulmonary Disease, Lung Diseases, Obstructive
Shanghai University of Traditional Chinese Medicine
Not applicable
60
Shanghai
2023-01-03
Recruiting
Small Extracellular Vesicle miRNAs as Predictive Biomarkers for Immunochemotherapy Efficacy in Extensive-stage Small Cell Lung Cancer
NCT07070011Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Shanghai Chest Hospital of Shanghai Jiao Tong University
Observational
38
Shanghai
2023-01-03
Recruiting
Effectiveness and Health Economics of Endoluminal Treatment of Autologous Arteriovenous Endovascular Fistula Failure
NCT06454396Hemodialysis Access Failure
RenJi Hospital
Observational
480
Shanghai
2023-01-01
Recruiting
Armatinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated Non-small Cell Lung Cancer
NCT05800223Non-small Cell Lung Cancer Metastatic
DrugAlmonertinib
Shanghai Cancer Hospital, China
Phase 3
300
Shanghai
2023-01-01
Recruiting
Clinical Study of Neoadjuvant Targeted Therapy for Ameloblastoma
NCT06653517Ameloblastoma, BRAF V600E Mutation Positive
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Phase 2
12
Shanghai
2023-01-01
Recruiting
Radiotherapy Combined With Immunochemotherapy in Metastatic Esophageal Squamous Cell Carcinoma
NCT05978193Esophageal Squamous Cell Carcinoma, Esophageal Cancer, Metastatic Esophageal Squamous Cell Carcinoma
Shanghai Chest Hospital
Phase 2
100
Shanghai
2023-01-01
Recruiting
Prophylactic Irradiation to the Contralateral Breast for BCAs Patients
NCT04960839Breast Cancer
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
323
Jiangxi, Shanghai, Hangzhou
2023-01-01
Recruiting
Prospective National Multi-center Registry of Obstructive Sleep Apnea Syndrome in Hypertensive Patients in China
NCT05735444Hypertension, Obstructive Sleep Apnea
Shanghai Jiao Tong University School of Medicine
Observational
633
Shanghai
2023-01-01
Recruiting
Pharmacometrics Analysis of Rivaroxaban in Chinese Children Aged Over 2 Years
NCT06993636Kawasaki Disease, Coronary Artery Aneurysm, Rivaroxaban, Anticoagulant Drugs
Children's Hospital of Fudan University
Observational
60
Shanghai
2023-01-01
Recruiting
Adjuvant Serplulimab and Trastuzuma and Chemotherapy in Her-2+ Gastric Cancer
NCT05975749Gastric Cancer
DrugSerplulimab
Fudan University
Phase 2
114
Shanghai
2023-01-01
Active, closed
Effects of Hemodialysis Plus Hemoperfusion in Maintenance Hemodialysis Patients: A Clinical Study
NCT05639010End Stage Renal Disease
Changhai Hospital
Not applicable
410
Shanghai
2023-01-01
By invitation
Optimized PGT-M Strategy for Patients With No Proband
NCT06722313De Novo Mutation, Preimplantation Genetic Testing, Without Proband
ShangHai Ji Ai Genetics & IVF Institute
Not applicable
5
Shanghai
2023-01-01
Recruiting
GPC3-directed CAR-T in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma
NCT05926726Hepatocellular Carcinoma
RenJi Hospital
Not applicable
12
Shanghai
2023-01-01
Recruiting
AI-Based Ultrasound Prediction of Pregnancy Outcomes in Placental-Related Fetal Growth Restriction (MVM-FGR): A Prospective Cohort Study
NCT07473739Fetal Growth Restriction (FGR)
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Observational
300
Shanghai
2023-01-01
Recruiting
Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer
NCT06121700Adenocarcinoma, Stomach Neoplasm, Gastroesophageal-junction Cancer, Oligometastatic Disease
Fudan University
Phase 2
55
Shanghai
2023-01-01
By invitation
Melatonin and Perinatal Outcomes in MVM-Related Fetal Growth Restriction (MIMVMFGR)
NCT07549295Fetal Growth Restriction (FGR)
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Phase 1
240
Shanghai
2023-01-01
Recruiting
Exploratory Study of MSLN-CAR T Cells Secreting PD1/CTLA-4 Nanoantibody for the Treatment of Advanced Solid Tumors
NCT06248697Solid Tumor
Shanghai Cell Therapy Group Co.,Ltd
Phase EARLY_PHASE1
16
Shanghai
2023-01-01
Not yet open
A Study of Sulfatinib on Relapsed or Refractory Drug Resistant Osteosarcoma
NCT05590572Osteosarcoma
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 1/2
148
Beijing, Jinan, Shanghai
2023-01
Recruiting
SNF Platform Study of HR+/ HER2-advanced Breast Cancer
NCT05594095Breast Neoplasm, Breast Cancer, Hormone Receptor Positive Tumor, HER2-negative Breast Cancer
DrugsCarrelizumab·SHR-A1921·Famitinib·SHR-A2009
Fudan University
Phase 2
620
Shanghai
2022-12-30
Recruiting
AssesSment of Early-deteCtion basEd oN liquiD Biopsy in PANCEATIC Cancer (ASCEND-PANCREATIC)
NCT05556603Cancer
Ruijin Hospital
Observational
7,062
Shanghai
2022-12-28
Recruiting
Clinical Study on the EBV CAR-T /TCR-T Cells in the Treatment of Nasopharyngeal Carcinoma
NCT05587543Nasopharyngeal Carcinoma
Fudan University
Phase EARLY_PHASE1
24
Shanghai
2022-12-28
Not yet open
Cognitive Impairment Cohort Study of the Elderly Population in SheMountain
NCT05667935Alzheimer Disease, Dementia, Neurodegenerative Diseases, Cognitive Impairment
Ruijin Hospital
Observational
2,000
Shanghai
2022-12-26
Recruiting
Combination of Gemcitabine, Albumin-paclitaxel , Sintilimab and Bevacizumab in Unresectable Gallbladder Cancer
NCT05757336Gallbladder Cancer, Initially Unresectable, the First Line Treatment
Lu Wang, MD, PhD
Phase 2
50
Shanghai
2022-12-22
Recruiting
Clinical Study of Tumor Treating Fields Combined with Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatment of Locally Advanced Pancreatic Cancer
NCT05653453Locally Advanced Pancreatic Cancer
Jiangsu Healthy Life Innovation Medical Technology Co., Ltd
Phase 3
512
Harbin, Jinan, Shanghai
2022-12-20
Active, closed
Prognostic Value of the AMR Measured After PPCI in STEMI Patients
NCT05653765Coronary Heart Disease, ST Elevation Myocardial Infarction
Henan Institute of Cardiovascular Epidemiology
Observational
2,663
Shangqiu, Xinxiang, Yongcheng, Zhengzhou, Shanghai
2022-12-20
Recruiting
Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC
NCT05652920Hepatocellular Carcinoma
OriCell Therapeutics Co., Ltd.
Phase 1/2
105
Beijing, Changsha, Changchun, Chengdu, Hangzhou, Lishui, Shanghai
2022-12-15
Active, closed
A Study of Daratumumab
NCT05438043Multiple Myeloma
DrugsCarfilzomib·Pomalidomide·Daratumumab·Lenalidomide
Janssen Research & Development, LLC
Phase 3
213
Beijing, Changchun, Chengdu, Fuzhou, Guangzhou, Hangzhou, Shanghai, Suzhou
2022-12-15
Active, closed
A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer
NCT05488314Carcinoma, Non-Small-Cell Lung
DrugsCapmatinib·Amivantamab
Janssen Research & Development, LLC
Phase 1/2
57
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Huizhou, Shanghai, Shenyang
2022-12-13
Recruiting
Safety and Efficacy Study of LX103 Treatment of X-Linked Retinoschisis (XLRS)
NCT05814952X-linked Retinoschisis
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Not applicable
12
Shanghai
2022-12-13
Recruiting
The Combination of Immunotherapy and Neoadjuvant Short-course Radiotherapy in Early Rectal Cancer
NCT05555888Early Low Rectal Cancer
Fudan University
Phase 2
34
Shanghai
2022-12-12
Active, closed
An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib
NCT05513001Chronic Spontaneous Urticaria
DrugsRemibrutinib treatment·Remibrutinib
Novartis Pharmaceuticals
Phase 3
696
Guangzhou, Wuhan, Wuxi, Changchun, Chengdu, Hangzhou, Beijing, Shanghai
2022-12-09
Recruiting
IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer
NCT05827796Pancreatic Cancer
DrugsKN046·IN10018·Albumin-Bound Paclitaxel·Gemcitabine
InxMed (Shanghai) Co., Ltd.
Phase 1/2
70
Shanghai
2022-12-08
Recruiting
A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.
NCT05487391Carcinoma, Non-Small-Cell Lung
Qilu Pharmaceutical Co., Ltd.
Phase 3
632
Shanghai
2022-12-08
Recruiting
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
NCT05579366High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
DrugsRina-S·Bevacizumab·Carboplatin·Pembrolizumab
Genmab
Phase 1/2
884
Beijing, Chongqing, Changsha, Nanchang, Changchun, Chengdu, Shanghai, Hangzhou
2022-12-07
Active, closed
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors
NCT05599984Advanced Solid Tumors
DrugsABBV-706·Budigalimab·Cisplatin·Carboplatin
AbbVie
Phase 1
288
Beijing, Wuhan, Shenyang, Shanghai
2022-12-05
Active, closed
Exploring the Effect of Colonic J-pouch in Anorectal Preservation Surgery for Ultra-low Rectal Cancer.
NCT06601985Rectum Cancer, Faecal Incontinence, Faecal Incontinence with Faecal Urgency, Low Anterior Resection Syndrome
Shanghai 10th People's Hospital
Observational
154
Shanghai
2022-12-01
Not yet open
A Combination Therapy Including Anti-PD-1 Immunotherapy in MSS Rectal Cancer With Resectable Distal Metastasis
NCT05359393Advanced Rectal Cancer, Liver Metastasis, Pulmonary Metastasis, Microsatellite Stable Colorectal Carcinoma
Fudan University
Phase 2
52
Shanghai
2022-12-01
Recruiting
The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer
NCT05628038Recurrent Rectal Cancer
Drugs5FU·Folinic acid·Irinotecan·Cetuximab
Fudan University
Phase 2
93
Shanghai
2022-11-30
Active, closed
Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis
NCT05588843Colitis Ulcerative
Sanofi
Phase 2
187
Guangzhou, Hangzhou, Hefei, Nanchang, Nanjing, Shanghai, Shenyang
2022-11-25
Active, closed
A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP)
NCT05394116Fibrodysplasia Ossificans Progressiva
DrugGaretosmab
Regeneron Pharmaceuticals
Phase 3
63
Shanghai
2022-11-21
Active, closed
Repeated Low-Level Red-Light Therapy for Shortening Axial Length
NCT05550740High Myopia, Refractive Errors, Eye Diseases
Shanghai Eye Disease Prevention and Treatment Center
Not applicable
30
Shanghai
2022-11-19
Active, closed
Digital Therapy for Fatty Liver Disease
NCT07007741Steatohepatitis, Nonalcoholic, Nonalcoholic Fatty Liver
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Not applicable
141
Shanghai
2022-11-19
Recruiting
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
NCT05623020Multiple Myeloma
DrugsElranatamab·Bortezomib·Daratumumab·Lenalidomide
Pfizer
Phase 3
1,116
Beijing, Fuzhou, Guangzhou, Wuhan, Nanjing, Suzhou, Changchun, Shanghai
2022-11-10
Active, closed
Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis
NCT05583227Eosinophilic Esophagitis
DrugTezepelumab
AstraZeneca
Phase 3
368
Beijing, Guangzhou, Hangzhou, Nanjing, Shanghai, Shenyang, Tianjin, Wuhan
2022-11-10
Active, closed
AK112 in Advanced Non-Small Cell Lung Cancer
NCT05499390Advanced Non-small-cell Lung Cancer
Akeso
Phase 3
398
Shanghai
2022-11-09
Rows per page Showing 3101–3200 of 3827
Previous 30 31 32 33 34 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-china/city/shanghai?page=32

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 3,827 of those studies with a site in Shanghai.

How many clinical trials are recruiting in Shanghai?

2,393 of the 3,827 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 737 have not yet opened recruitment, 588 are active but closed to new participants, and 109 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.